奧泰生物(688606.SH):“新增年產2.65億人份體外診斷試劑的產業化升級技術改造項目”已實現投產
格隆匯1月2日丨奧泰生物(688606.SH)公佈,連日來,隨着新冠肺炎疫情防控新十條措施、新冠病毒抗原檢測應用方案相繼出台,國內對新冠病毒抗原檢測試劑的需求大幅提升。針對抗原檢測試劑等醫療物資供應緊張的情況,公司積極響應政府的號召,努力供應國內抗原檢測試劑對應市場,嚴格落實生產規範防範措施,加緊作業,執行車間機器不停轉、員工輪崗、錯峯休假的生產計劃,確保最大限度釋放產能,保障國內抗原檢測試劑的生產和供應。
公司首次公開發行募集資金淨額1,643,266,906.25元。截至目前,公司募投項目“新增年產2.65億人份體外診斷試劑的產業化升級技術改造項目”已實現投產,並取得一定經濟效益,有效提升公司重點醫療物資生產供應能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.